Results 181 to 190 of about 65,066 (300)
Earth-mass planets with He atmospheres in the habitable zone of Sun-like stars. [PDF]
Lammer H +6 more
europepmc +1 more source
S-index periodicity detection based on multiple random spectral observations. [PDF]
Shen YF.
europepmc +1 more source
In normal (nontolerant) cells, CD14 is crucial for both LPS uptake and LPS signaling. In LPS‐tolerant cells, in which LPS‐induced TNF‐α and IFN‐β production is suppressed, there is a dramatic increase in surface CD14 expression. The overexpressed CD14 in LPS‐tolerant cells is responsible for the enhanced LPS uptake without inducing pro‐inflammatory ...
Saeka Nishihara +3 more
wiley +1 more source
A young progenitor for the most common planetary systems in the Galaxy. [PDF]
Livingston JH +41 more
europepmc +1 more source
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha +4 more
wiley +1 more source
Models and observational predictions of dust traps in protoplanetary discs. [PDF]
Pinilla P.
europepmc +1 more source
Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss +12 more
wiley +1 more source
Using a neural network approach and starspots dependent models to predict effective temperatures and ages of young stars. [PDF]
Tarantino M +4 more
europepmc +1 more source
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
The culture of JACMP, the sanctity of editorial independence, and why your ego is not your amigo. [PDF]
Mills MD.
europepmc +1 more source

